Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 3/20 | 0.58 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | ELANE | P08246 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | BCL2 | P10415 | 2/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1712245 | 0.93 | ELANE (0.55) | TTRCYP1A1CYP1A2ELANEKMT2A | |
| SCHEMBL6905214 | 0.82 | TTR (0.64) | TTRCYP1A1CYP1A2KMT2AMEN1 | |
| SCHEMBL985103 | 0.81 | TTR (0.62) | TTRCYP1A1CYP1A2ELANEKMT2A | |
| SCHEMBL14124313 | 0.78 | ELANE (0.55) | TTRCYP1A1CYP1A2ELANEKMT2A | |
| SCHEMBL11640489 | 0.78 | TTR (0.58) | TTRCYP1A2ELANEKMT2AMEN1 | |
| SCHEMBL9846479 | 0.78 | TTR (0.58) | TTRCYP1A1CYP1A2KMT2AMEN1 | |
| Pachybasin SCHEMBL7624909 | 0.78 | MAPT (0.75) | TTRCYP1A1CYP1A2ELANEKMT2A | |
| Pachybasin SCHEMBL31536859 | 0.78 | MAPT (0.75) | TTRCYP1A1CYP1A2ELANEKMT2A | |
| SCHEMBL29191819 | 0.78 | TTR (0.58) | TTRCYP1A1CYP1A2ELANEKMT2A | |
| SCHEMBL11404943 | 0.78 | CYP1A1 (0.51) | TTRCYP1A1CYP1A2ELANEKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107744795-A | A kind of hydrogenation-dechlorination catalyst converter | 徐州工程学院 | 2018-03-02 | — | — | CN | disclosed |
| US-9096536-B2 | Asymmetrically substituted anthrapyridazone derivatives as cytostatics | BS-154 S.P. ZO.O. (PL) | 2015-08-04 | — | — | US | disclosed |
| EP-2697205-A1 | ASYMMETRICALLY SUBSTITUTED ANTHRAPYRIDAZONE DERIVATIVES AS CYTOSTATICS | BS-154 SP. Z O.O. (PL) | 2014-02-19 | — | — | EP | disclosed |
| US-20140031357-A1 | ASYMMETRICALLY SUBSTITUTED ANTHRAPYRIDAZONE DERIVATIVES AS CYTOSTATICS | BS-154 SP. Z O.O. (PL) | 2014-01-30 | — | — | US | disclosed |
| WO-2012141604-A1 | ASYMMETRICALLY SUBSTITUTED ANTHRAPYRIDAZONE DERIVATIVES AS CYTOSTATICS | INSTYTUT FARMACEUTYCZNY (PL) | 2012-10-18 | — | — | WO | disclosed |
| US-4355012-A | Mixed anthraquinonedisulfonic acids | AMERICAN COLOR & CHEMICAL CORPORATION (US) | 1982-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031357-A1 | ASYMMETRICALLY SUBSTITUTED ANTHRAPYRIDAZONE DERIVATIVES AS CYTOSTATICS | ABCC1, ABCC3, ABCB1 | TTR 4656/4885CYP1A1 866/4885CYP1A2 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.